We are proud to forge a new partnership with Berlin-based health tech startup, theblood, to support the development and validation of women’s health diagnostics based on menstrual blood.
The collaboration is designed to open up a new, non-invasive path for female-specific health diagnostics through the establishment of a robust scientific and regulatory foundation that builds long-term trust in women’s health care.
As an independent quality and validation partner to theblood, we will contribute our global pharma expertise in bioanalytical sciences and accompany theblood in its exploration of menstrual blood as a diagnostic matrix. By embedding the highest quality standards early in the innovation process, SGS helps to ensure that novel diagnostic approaches are developed with scientific rigor and regulatory awareness from the outset.
Menstrual blood is increasingly recognized as a promising source of female-specific health data. It contains biomarkers that could transform health monitoring, particularly in relation to inflammatory-related disorders such as endometriosis, polycystic ovary syndrome (PCOS), and other fertility-related conditions. Despite these possibilities, menstrual blood remains an underexplored biological matrix where medical applications require a high level of scientific rigor, quality and trust.
“Innovative diagnostics only gain relevance when they are supported by scientific credibility and quality,” says Sheida Hoenlinger, Director Business Development at SGS in Austria, Business Assurance Cosmetics & Pharma DACH, who manages the collaboration. “Through this partnership, we are accompanying the responsible development of a new matrix and its path toward trusted applications.”
theblood focuses on the systematic exploration of menstrual blood as a non-invasive, clinically relevant biological matrix. Its work aims to address long-standing data gaps in women’s health and unlock new diagnostic perspectives that contribute to earlier detection, improved medical understanding and better health outcomes for women.
“With SGS supporting us on this journey, we are ensuring that the exploration of menstrual blood is guided by scientific rigor, quality and long-term trust,” says Isabelle Guenou, Founder and CEO of theblood.
For new diagnostic matrices to be clinically relevant and adopted, scientific and regulatory stakeholders require evidence that results are accurate, reproducible, generated through controlled- and quality-assured processes. Robust validation establishes trust and supports wider adoption, not only among regulators and clinicians, but also among patients whose health decisions depend on reliable data.
This partnership demonstrates our shared commitment to advancing women’s health, supporting the development of credible non-invasive diagnostics, and contributing to a more inclusive and evidence-based future for healthcare.
Explore the full range of SGS Pharma testing, formulation and clinical support services
For further information, please contact:
Rayane Mohamad
Director Scientific & Technical Expertise, Cosmetics & Health Science
t: +41 (22) 7399136
SGS is the world’s leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of over 100,000 dedicated professionals. With more than 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability.
Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and a portfolio of trusted specialized brands, including Applied Technical Services, Brightsight, Bluesign and Nutrasource.
SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN SW).
